Current and historical daily PE Ratio for Keymed Biosciences Inc (
HKSE:02162
) from 2021 to May 30 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Keymed Biosciences stock (HKSE:02162) PE ratio as of May 30 2024 is 0.
More Details
Keymed Biosciences Inc (HKSE:02162) PE Ratio (TTM) Chart
Keymed Biosciences Inc (HKSE:02162) PE Ratio (TTM) Historical Data
View and export this data going back to 2021. Start your Free Trial
Total 715
- 1
- 2
- 3
- 4
- 5
- 6
- 8
| Keymed Biosciences PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-05-31 | At Loss | 2024-03-22 | At Loss |
| 2024-05-30 | At Loss | 2024-03-21 | At Loss |
| 2024-05-29 | At Loss | 2024-03-20 | At Loss |
| 2024-05-28 | At Loss | 2024-03-19 | At Loss |
| 2024-05-27 | At Loss | 2024-03-18 | At Loss |
| 2024-05-24 | At Loss | 2024-03-15 | At Loss |
| 2024-05-23 | At Loss | 2024-03-14 | At Loss |
| 2024-05-22 | At Loss | 2024-03-13 | At Loss |
| 2024-05-21 | At Loss | 2024-03-12 | At Loss |
| 2024-05-20 | At Loss | 2024-03-11 | At Loss |
| 2024-05-17 | At Loss | 2024-03-08 | At Loss |
| 2024-05-16 | At Loss | 2024-03-07 | At Loss |
| 2024-05-14 | At Loss | 2024-03-06 | At Loss |
| 2024-05-13 | At Loss | 2024-03-05 | At Loss |
| 2024-05-10 | At Loss | 2024-03-04 | At Loss |
| 2024-05-09 | At Loss | 2024-03-01 | At Loss |
| 2024-05-08 | At Loss | 2024-02-29 | At Loss |
| 2024-05-07 | At Loss | 2024-02-28 | At Loss |
| 2024-05-06 | At Loss | 2024-02-27 | At Loss |
| 2024-05-03 | At Loss | 2024-02-26 | At Loss |
| 2024-05-02 | At Loss | 2024-02-23 | At Loss |
| 2024-04-30 | At Loss | 2024-02-22 | At Loss |
| 2024-04-29 | At Loss | 2024-02-21 | At Loss |
| 2024-04-26 | At Loss | 2024-02-20 | At Loss |
| 2024-04-25 | At Loss | 2024-02-19 | At Loss |
| 2024-04-24 | At Loss | 2024-02-16 | At Loss |
| 2024-04-23 | At Loss | 2024-02-15 | At Loss |
| 2024-04-22 | At Loss | 2024-02-14 | At Loss |
| 2024-04-19 | At Loss | 2024-02-09 | At Loss |
| 2024-04-18 | At Loss | 2024-02-08 | At Loss |
| 2024-04-17 | At Loss | 2024-02-07 | At Loss |
| 2024-04-16 | At Loss | 2024-02-06 | At Loss |
| 2024-04-15 | At Loss | 2024-02-05 | At Loss |
| 2024-04-12 | At Loss | 2024-02-02 | At Loss |
| 2024-04-11 | At Loss | 2024-02-01 | At Loss |
| 2024-04-10 | At Loss | 2024-01-31 | At Loss |
| 2024-04-09 | At Loss | 2024-01-30 | At Loss |
| 2024-04-08 | At Loss | 2024-01-29 | At Loss |
| 2024-04-05 | At Loss | 2024-01-26 | At Loss |
| 2024-04-03 | At Loss | 2024-01-25 | At Loss |
| 2024-04-02 | At Loss | 2024-01-24 | At Loss |
| 2024-03-28 | At Loss | 2024-01-23 | At Loss |
| 2024-03-27 | At Loss | 2024-01-22 | At Loss |
| 2024-03-26 | At Loss | 2024-01-19 | At Loss |
| 2024-03-25 | At Loss | 2024-01-18 | At Loss |
Keymed Biosciences Inc (HKSE:02162) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Keymed Biosciences Inc
ISIN : KYG5252B1023
Compare
Compare
Traded in other countries / regions
02162.Hong Kong64Z.Germany IPO Date
2021-07-08Description
Keymed Biosciences Inc is a biotechnology company with multiple clinical-stage assets. The company is focused on the in-house discovery and development of biological therapies that address large underserved medical needs in the autoimmune and oncology therapeutic areas. Its clinical-stage drug candidates include CM310, CM326, CM313, and CM336 among others. The company is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment. Geographically, it generates a majority of its revenue from overseas markets and the rest from Mainland China.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers